Ann Mauer, MD
Hematology-Oncology · Chicago, ILNPI 1891705463
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,250 of the $1,499 with a category attached, or 83.4%. Intuitive Surgical accounts for 83.4% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $1,373 and has fallen 94.2% since, to $79 in 2025.
Across 9 payments — averaging $166.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$1K
- Merck$109
- Ipsen Biopharmaceuticals, Inc$79
- Johnson & Johnson$18
- E.r. Squibb & Sons, L.L.C.$17
- Pfizer$15
- plus $12 from 1 others
Across 9 payments — averaging $4196.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Products Limited$28K
- Pfizer$10K
What the payments were for
- Travel & lodging$1,25083%
- Food & beverage$1278%
- Education$1228%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 3 | $1,250 |
| Merck | 1 | $109 |
| Ipsen Biopharmaceuticals, Inc | 1 | $79 |
| Johnson & Johnson | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Pfizer | 1 | $15 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,231
How this compares
Too few hematology-oncology providers in Illinoisto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 391 | $7,653 |
| Tamoxifen Citrate | 76 | $1,736 |
| Exemestane | 18 | $1,343 |
| Letrozole | 41 | $587 |
| Dexamethasone | 14 | $399 |
| Triamcinolone Acetonide | 16 | $324 |
| Prochlorperazine Maleate | 27 | $202 |
| Alendronate Sodium | 21 | $180 |
| Ondansetron OdtOndansetron | 12 | $157 |
| Prednisone | 17 | $33 |
Paid to pharmacies, not to this prescriber.
Other hematology-oncology in Chicago
- Joanna StankiewiczChicago$2K
- Samir UndeviaChicago$2K
- Shawn KothariChicago$0
- Brandon BungoChicago$0
- Jane ChurpekChicago$0
- Michael HawkingChicago$0
- Megan RandallChicago$0
- John ShowelChicago$0
- Tabraiz MohammedChicago$0
- Sujatha RaoCarbondale$933
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.